| | The Right LIMS for COVID-19 Research LabVantage COVID-19 LIMS keeps pace with increasing COVID-19 sample volumes and research studies. Learn how one research center uses extraction and testing workflows, CDC test methods, and more to fight the coronavirus pandemic. Download our report. |
Pfizer, BioNTech nab fast track tag, prep for major phase 3 COVID-19 vax test this month Hospitals struggle with PPE shortages amid new COVID-19 surges Moderna's COVID-19 vaccine could cruise to $5B in sales—or more, analysts say Senate Democrats demand $25B for widespread COVID-19 vaccine distribution Hedge fund urges Qiagen to rethink Thermo Fisher's $11.5B takeover offer, as COVID-19 fuels testing demand: FT Healthcare roundup: Insurers urge Congress to fund COVID-19 testing Biopharma roundup: FDA to resume U.S. inspections with COVID-19 caveats: Hahn; Junshi taps Lonza for production of Lilly-partnered antibody FDA complicates 'chaotic' federal COVID-19 response with pledge to resume domestic inspections 10M people likely to drop out of employer coverage this year due to COVID-19: report Osmotica bucks pandemic trend with in-person sales calls for eye drug launch Featured Story | By Ben Adams Pfizer and German mRNA partner BioNTech have grabbed an FDA fast track label as they look to start a late-stage, 30,000-patient COVID-19 vaccine test before the month is out. read more |
| |
|---|
|
Top Stories By Robert King Four months into the COVID-19 crisis, the PPE supply chain has not yet caught up, and hospitals are continuing to reuse protective equipment, especially for those systems in new virus hot spots. read more By Eric Sagonowsky Moderna has never scored a commercial approval for any of its drugs or vaccines, but analysts with Jefferies think the company has a winner in its COVID-19 shot. The team is projecting around $2 billion in 2021 sales, and $5 billion in sales over the next few years. read more By Robert King Senate Democrats released a plan to facilitate the widespread distribution of a COVID-19 vaccine, including a demand of $25 billion to ensure any vaccine is widely distributed. read more By Conor Hale The world has changed since Thermo Fisher Scientific reached a hard-fought, $11.5 billion agreement to acquire Qiagen, announced in the first days of March after months of negotiations and public rumors. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Jefferies analysts expect Moderna's COVID-19 shot candidate to win approval early next year and possibly pull in billions for the company. China's Junshi Biosciences licensed tech from Swiss contract manufacturer Lonza to help produce its Eli-Lilly partnered COVID-19 antibody hopeful. Plus, the WHO's director warned that countries aren't doing enough to stop the virus. read more By Kyle Blankenship The FDA's usual facility inspections have been on hold for months because of COVID-19—and pharma isn't happy. Now, after hearing calls from all levels of the drug industry, the agency says it will kick off inspections again. But it's far from a full-scale restart. read more By Paige Minemyer More than 10 million people could drop out of employer-sponsored health coverage by December thanks to job losses linked to COVID-19, a new report finds. read more By Fraiser Kansteiner With its new FDA approval for Upneeq, Osmotica Pharmaceuticals faces the task of marketing a reformulated nasal spray to millions of people with droopy eyelid, many of whom don't even know it's considered a disorder, much less a treatable one. read more |
